Premium
A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer
Author(s) -
Lebeck Lee Cody M.,
Ziogas Ioannis A.,
Agarwal Rajiv,
Alexopoulos Sophoclis P.,
Ciombor Kristen K.,
Matsuoka Lea K.,
Brown Daniel B.,
Eng Cathy
Publication year - 2022
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.34170
Subject(s) - medicine , liver transplantation , medline , cochrane library , colorectal cancer , systematic review , cancer , meta analysis , oncology , transplantation , intensive care medicine , political science , law
The 5‐year overall survival rate of a patient with unresectable metastatic colorectal cancer is poor at approximately 14%. Similarly, historical data on liver transplantation (LT) in those with colorectal liver metastases (CRLM) showed poor outcomes, with 5‐year survival rates between 12% and 21%. More recently, limited data have shown improved outcomes in select patients with 5‐year overall survival rates of approximately 60%. Despite these reported survival improvements, there is no significant improvement in disease‐free survival. Given the uncertain benefit with this therapeutic approach and a renewed investigational interest, we aimed to conduct a contemporary systematic review on LT for CRLM. A systematic review of the literature was performed according to the preferred reporting items for systematic reviews and meta‐analysis statement. English articles reporting on data regarding LT for CRLM were identified through the MEDLINE (via PubMed), Cochrane Library, and ClinicalTrials.gov databases (last search date: December 16th, 2021) by 2 researchers independently. A total of 58 studies (45 published and 13 ongoing) were included. Although early retrospective studies suggest the possibility that some carefully selected patients may benefit from LT, there is minimal prospective data on the topic and LT remains exploratory in the setting of CRLM. Additionally, several other challenges, such as the limited availability of deceased donor organs and defining appropriate selection criteria, remain when considering the implementation of LT for these patients. Further evidence from ongoing prospective trials is needed to determine if and to what extent there is a role for LT in patients with surgically unresectable CRLM.